K
kupando
A pioneering biopharmaceutical company developing a TLR 4/7 agonist that stimulates innate immunity
About kupando
Kupando is a Schönefeld (Brandenburg) biopharmaceutical company founded in 2018 by CEO Dr Johanna Holldack, building on innate-immunity research from Professor Dennis Carson’s laboratory at UC San Diego. Its lead candidate KUP101 is a dual TLR4/TLR7 agonist co-encapsulated in a liposomal formulation designed to stimulate innate and trained immunity for tissue-agnostic treatment of solid tumours and for prevention/treatment of infectious disease including antimicrobial-resistant pathogens; the AMR programme has been sponsored by Germany’s Federal Ministry of Research, Technology and Space. After an initial Series A that brought equity support from Remiges Ventures, LifeCare Partners, Brandenburg Kapital, HTGF, Ventura Biomed Investors and family offices, in March 2026 Kupando secured an additional €10 million Series A extension again led by Remiges and co-led by LifeCare Partners with existing investors and new investor Carma Fund, bringing total Series A funding to €23 million to fund a planned Phase 1b / first-in-human oncology study of KUP101 and accelerate infectious-disease preclinical programmes. Sources: Kupando 18 Mar 2026; HTGF; The Next Web.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Schönefeld, Germany
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 78.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Hard Tech, Woman Founder, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2026 | $11M | $72M | Remiges Ventures · LifeCare Partners · Brandenburg Kapital · HTGF | ↗ |
| EARLY VC✓Equity / VC | Jun 2025 | $0 | — | HTGF · LifeCare Partners · Eckenstein-Geigy-Stiftung · Ventura BioMed Investors | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for kupando is 90 monthly website visits, up 50% over the last three months. kupando's team grew 9.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
- LPLifeCare Partners
HTGF- VIVentura BioMed Investors
Brandenburg Kapital
Eckenstein-Geigy-Stiftung
CARMA FUND Management- AFArkadien Finanz
Remiges Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about kupando on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See kupando’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.